Roman Pharma’s core strength lies in our ability to excel in developing technologically complex products through focused teams in formulations, process chemistry and analytical development following a strategy of development of difficult to mimic generics in defined specialty areas.
The company’s research commitment usually is between 7-8% of revenue and more million has been spent for generic research since 2009. Every year, Roman plans to brings about 30 new products to the Indian market, scales up 25 API including drug master files for US and Europe and develops and files for more than 30 ANDAs for the US. As of June 2012, 12 products have been approved by the USFDA for sale in the United States and 50 filings await approval.
Roman Pharma, along with its subsidiaries, has 4 state-of-the-art R&D centers across the world with more than 200 scientists employed.